首页> 外文期刊>Journal of Crohn’s & colitis >Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
【24h】

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

机译:ECCO / ESPGHAN关于小儿克罗恩病医疗管理的共识指南

获取原文
获取原文并翻译 | 示例
           

摘要

Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.
机译:与成年患者相比,患有克罗恩氏病(CD)的儿童和青少年通常病情更复杂。此外,CD对患者生长,青春期和情绪发育的潜在影响强调了对儿童发作性CD的特定管理策略的需求。为了制定第一个以证据为基础且共识驱动的小儿发作性CD指南,在欧洲克罗恩病和结肠炎组织以及欧洲小儿胃肠病,肝病和营养学会公开召集之后,由33名IBD专家组成了专家小组。目的是在对现有证据进行彻底审查的基础上,对患有CD的儿童和青少年的医学治疗和长期管理提供最新的指导,并根据不同的临床情况,基于受益风险分析制定个性化的治疗算法。在尚未完成生长的儿童和青少年中,独家肠内营养(EEN)由于其出色的安全性而成为首选的诱导疗法,其安全性优于皮质类固醇,后者具有诱导缓解的潜力。大多数患有小儿发作性CD的患者需要基于免疫调节剂的维持治疗。专家们讨论了可能预示不良疾病结果的几种因素(例如严重的肛周瘘管病,严重的狭窄/穿透性疾病,严重的生长迟缓,胰腺炎,尽管进行了充分的诱导治疗仍持续存在严重的疾病),这些因素可能会诱发抗TNF-基于自上而下的方法。这些指南旨在为照顾儿童和青少年CD的(儿科)胃肠病医生提供实用的(尽可能基于证据的)答案。它们并不意味着成为规则或法律标准,因为存在许多不同的临床情况,需要这些指南未涵盖或与之不同的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号